Form 4: Syros Pharmaceuticals Chief Medical Officer Sells Shares

Syros Pharmaceuticals' Chief Medical Officer, David Roth, sold 12,099 shares of common stock at an average price of $0.1969 per share on November 18, 2024.

Summary

• David Roth, the Chief Medical Officer of Syros Pharmaceuticals, sold 12,099 shares of the company's common stock on November 18, 2024.
• The shares were sold at a weighted average price of $0.1969 per share.
• The sale was executed in multiple transactions with prices ranging from $0.1968 to $0.1975 per share.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale by an officer, with no inherent positive or negative sentiment.

Industry Context

This is a routine SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the transactions of company officers.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical insider trading activity.
• Similar filings are made by officers and directors of companies like Amgen, Gilead, and Biogen when they buy or sell shares of their respective companies.

Stakeholder Impact

• The sale of shares by a company officer may be of interest to shareholders, but it is a routine transaction.

Key Dates

Keywords

Syros Pharmaceuticals, David Roth, stock sale, insider trading, common stock, Chief Medical Officer